06185 CANSINOBIO
- 20.800
- 0.0000.00%
CANSINOBIO News
Changes in Hong Kong stocks | Cansino Biotech (06185) rose more than 6% in the intraday period, UBS says MCv4 business revenue may increase 50% this year
The Zhitong Finance App learned that Cansino Biotech (06185) rose more than 6% in the intraday period. As of press release, it had risen 4% to HK$20.8, with a turnover of HK$24.9353 million. UBS published research stating that as the number of births falls further, the market focus will continue to shift from child vaccines to adult vaccines. At the same time, it is predicted that, driven by the increasing penetration rate of the MCv4 vaccine, Cansino's MCv4 business revenue will increase by 50% in 2024. According to the bank, the penetration rate of the Cansino Biotech MCV4 vaccine is relatively low, and the launch of the new product brings rich catalysts, setting the target price of Cansino H shares at
Featured announcements | BeiGene's Q1 revenue increased nearly 70% year on year; GAC's sales fell nearly 25% year on year in April
① BeiGene's revenue increased by nearly 70% in the first quarter. What is the profit situation? ② GAC's sales volume fell by about 24% during the year. How much was the impact on sales in April?
Cansino Biotech (06185.HK) Purchases Structured Deposits
Glonghui, May 8, 丨 Cansino Biotech (06185.HK) announced that on May 8, 2024, the company and Bohai Bank signed a structured deposit agreement VI with Bohai Bank. Based on this, the company agreed to purchase a structured deposit with a principal amount of RMB 200 million from Bohai Bank.
Agency: The synthetic biology sector showed a high increase in Q1 performance, and policy expectations accelerated valuation repair
Currently, the core competitiveness of biological manufacturing companies lies in product development and implementation capabilities. They are optimistic about targets with successful cases, leading positions, high-quality product reserves, and a boom in downstream demand.
Cansino (688185): MCv4 continuous release cost control has seen initial results
The 1Q24 results are in line with our expectations. The company announced 1Q24 results: revenue of 114 million yuan, an increase of 13.65% over the previous year; net loss to mother of 170 million yuan. The results are in line with our expectations. The development trend MCV4 is performance
Hong Kong stocks started “booming” in May! The Hang Seng Index reclaimed the 18,000 mark, and in April, Demon Stock added another 30% assist
On May 2, Hong Kong stocks ushered in the first trading day of May, and the three major stock indexes continued their major counterattack!
Changes in Hong Kong stocks | Cornerstone Pharmaceutical-B (02616) rose more than 26%, leading the innovative drug concept, ASCO catalyzes market conditions, institutions are optimistic about policy+health insurance marginal improvement
Zhitong Finance App learned that innovative drug concept stocks showed strong performance. As of press release, Cornerstone Pharmaceutical-B (02616) rose 26.14% to HK$1.11; Cansino Biotech (06185) rose 16.91% to HK$20.95; Gacos-B (01167) rose 14.2% to HK$1.93; Nuocheng Jianhua (09969) rose 12.31% to HK$5.2; Rongchang Biotech (09995) rose 10.2% to HK$30.8. According to the news, the research title of the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting was on April 25
Changes in Hong Kong stocks 丨 Biotech stocks continue to strengthen, the cornerstone pharmaceutical industry rises nearly 23%
Glonghui, May 2 | Cornerstone Pharmaceuticals rose nearly 23%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmaceutical Kangde rose nearly 8.5%.
Hong Kong biotechnology stocks continued to strengthen. Cornerstone Pharmaceuticals rose nearly 23%, Gacos rose more than 14%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmacom Kangde rose nearly 8.5%.
Hong Kong biotechnology stocks continued to strengthen. Cornerstone Pharmaceuticals rose nearly 23%, Gacos rose more than 14%, Cansino Biotech rose nearly 14%, Lepu Biotech rose more than 10%, and Pharmacom Kangde rose nearly 8.5%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
The Hang Seng Index rose more than 2%, the Hang Seng Technology Index rose 3.7%, Hong Kong biotech stocks rose higher, Cansino Biotech rose more than 10%, and Rongchang Biotech rose more than 6%.
Changes in Hong Kong stocks | Cansino Biotech fell more than 5%, and its loss increased to 170 million yuan in the first quarter. It plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
Cansino Biotech (06185) fell by more than 5%. As of press release, it was down 5.11% to HK$17.84, with a turnover of HK$15.417,300.
Cansino Biotech (06185) plans to transfer AD5-eBoV and its global commercialization rights to the drug Cansino
Cansino Biotech (06185) announced that the company plans to sign a “Product Transfer and Technology License Agreement” with Shanghai Pharmaceutical Cansino, approximately...
康希諾生物：截至2024年3月31日止三個月的第一季度報告
Express News | Cansino: Plans to sign a product transfer and technology licensing agreement with Shanghai Pharmaceutical Cansino
Express News | Cansino: Q1 revenue of 114 million yuan, up 13.65% year on year; Q1 net loss of 170 million yuan.
Changes in Hong Kong stocks | Cansino Biotech (06185) is now up more than 4% Hib vaccine clinical trial approved, PBPV clinical trial has achieved positive initial results
The Zhitong Finance App learned that Cansino Biotech (06185) is now up more than 4%, with a cumulative increase of more than 18% during the month. As of press release, it rose 4.1% to HK$18.8, with a turnover of HK$17.022,600. According to the news, Cansino Biotech recently announced that the freeze-dried Haemophilus influenzae type b (Hib vaccine) conjugate vaccine (Hib vaccine) developed by the company has been approved by the China National Drug Administration and can carry out related clinical trials. Haemophilus influenzae is a gram-negative bacillus and is one of the most important pathogens of acute lower respiratory infections in children. Cansino Biotech also previously announced the recombinant pneumonia developed by the company
康希諾生物：2023年度報告
Changes in Hong Kong stocks | Pharmaceutical stocks strengthened in the afternoon, and the innovative drug policy showed a positive trend, and the sector is expected to continue to warm up after the second quarter
Pharmaceutical stocks strengthened in the afternoon. As of press release, Laikai Pharmaceutical-B (02105) rose 13.67% to HK$6.07; Conoa-B (02162) rose 13.21% to HK$33; and Pharmaceuticals (02268) rose 7.52% to HK$20.15.
Changes in Hong Kong stocks | Cansino Biotech (06185) once rose nearly 6% and freeze-dried Haemophilus influenzae type b conjugate vaccine was approved for clinical trials
At one point, Cansino Biotech (06185) rose nearly 6%. As of press release, it rose 4.69% to HK$18.32, with a turnover of HK$8.3079 million.
The majority of Hong Kong pharmaceutical stocks rose, and Pharmacovigilance rose more than 8%
Glonghui, April 23 | Pharmacovigilance increased by more than 8%, Cansino Biotech increased by more than 5%, and Pharmaceutical Kangde rose nearly 3%.
Analysis
Price Target
No Data
